Press Releases Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Delayed Nasdaq Other stock markets 18:08:58 02/05/2024 BST			5-day change	1st Jan Change
10.37 ^USD	-1.05%		+6.69%	-5.30%

04-30	Guggenheim Starts Precision BioSciences With Buy Rating, $19 Price Target	MT
04-16	Precision BioSciences Opts to Regain Rights to 3 Programs From Eli Lilly Unit Collaboration	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Precision BioSciences Announces Late-Breaking Poster Presentation at the European Association for Study of the Liver (EASL) Congress 2024	05-01	BU
Precision BioSciences Announces Return of Programs and Conclusion of Collaboration with Prevail Therapeutics	04-16	BU
Precision BioSciences: Q4 Earnings Snapshot	03-27	AQ
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update	03-27	BU
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024	03-20	BU
Precision BioSciences Presents Preclinical Data Highlighting PBGENE-PMM as a Potential Therapy for Primary Mitochondrial Myopathy	03-19	BU
IECURE SECURES APPROVAL FROM U.K. MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY TO EXPAND THE OTC-HOPE STUDY OF ECUR-506	03-07	AQ
Precision BioSciences Announces MHRA Approval for Partner iECURE to Expand Phase 1/2 Clinical Trial of ARCUS Gene Editing Program in OTC Deficiency	03-06	BU
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	03-04	AQ
Precision BioSciences Announces $40.0 Million Offering of Common Stock and Warrants	03-01	BU
Precision BioSciences Announces Proposed Public Offering of Common Stock and Warrants	02-29	BU
Precision BioSciences Announces Non-Exclusive Patent License Agreement with Caribou Biosciences	02-20	BU
Precision BioSciences Receives Pre-IND Feedback from US FDA for PBGENE-HBV as it Advances Towards Clinical Readiness	02-14	BU
Precision BioSciences Promotes Naresh Tanna to Vice President of Investor Relations	02-13	BU
Precision BioSciences to Effect a Reverse Stock Split	02-12	AQ
Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases	02-12	BU
Precision BioSciences to Effect a Reverse Stock Split	02-09	BU
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision's Allogeneic CD19 CAR T Cell Therapy	01-10	AQ
TG Therapeutics Announces Global License Agreement with Precision BioSciences for the Development and Commercialization of Precision’s Allogeneic CD19 CAR T Cell Therapy Program for the Treatment of Autoimmune Diseases	01-09	AQ
Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases	01-09	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Precision BioSciences, Inc.

Equities

DTIL

US74019P2074

Press Releases

Filters